-- Several biosimilars, biologics and non-biologics are in the final stages of development and will reach the market soon, Finds Frost & Sullivan
MOUNTAIN VIEW, California, April 23, 2015 /PRNewswire/ -- The rheumatoid arthritis therapeutics market is dominated by three tumor necrosis factor (TNF) inhibitors – Enbrel, Humira and Remicade. Due to their extensive clinical history and positive risk versus benefit profiles, these agents are likely to retain their market share. Nevertheless, the market for other rheumatoid arthritis therapeutics is considerable as many patients do not respond well to TNF inhibitors.
New analysis from Frost & Sullivan, Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market (http://bit.ly/1OzbpNG), finds that 40 drugs for the treatment of rheumatoid arthritis are under development. Of these 14 are in the third phase of clinical trials. R&D is focused on TNF, interleukin, janus kinase (JAK) inhibitors and anti-cluster of differentiation (CD) products.
For complimentary access to more information on this research, please visit: http://bit.ly/1DtLGzX.
"With drug manufacturers turning the spotlight on increasing drug efficacy, safety and lifestyle quality, the move from subcutaneous to oral administration is gathering pace," said Frost & Sullivan Life Sciences Industry Analyst Lucila Rocca. "Hence, the market is expected to see a flood of several oral therapies with equal or better efficacy and safety than biologics."
Biologics usually have a poor safety profile which is recognized late in the development stage, after significant investment has been made. Further, the high cost of biologics makes these therapies inaccessible to numerous patients, forcing them to skip or discontinue treatment. While highly effective in the management of rheumatoid arthritis, immunosuppressive therapy such as anti-TNF may generate risks as a result of a compromised immune system.
"As a result, biosimilars expect to be a viable alternative for patients who are unable to purchase biologics. They will also be the preferred choice for governments and private insurance companies looking to limit expenditure," noted Rocca. "The availability of these new drugs and the ensuing marketing efforts of competitors will generate renewed interest and awareness on rheumatoid arthritis, prompting increased diagnosis and market expansion."
Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market is a Market Insight that is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. This study evaluates the market for prescription drugs and biologics for the long-term treatment of RA prescribed in addition to standard of care. The study takes into account products in the market as well as those in development and discusses market challenges, drivers and restraints.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market
Corporate Communications – North America
SOURCE Frost & Sullivan